Program
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Sinocelltech Group.
Furthest: phase 3, since Jan 9, 20262 company-led studies, 2 open or runningNext primary completion: Jul 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinocelltech Group | 22 open or running | phase 3since Jan 9, 2026 | Mar 5, 2024 | Jul 2027phase 3 · NCT07362459 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 5, 2024First study: phase 2 study in Advanced Malignant Solid TumoursFirst studyNCT06304818 · 515 planned
- Jan 9, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedNCT07362459 · 246 planned · China
Ahead
- Jul 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07362459
- Dec 30, 2027Primary completion: phase 2 study in Advanced Malignant Solid TumoursNCT06304818
TargetBeta
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| tivunatamig | Pfizer | phase 3 | 15 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010 | Merck | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039Arule | Minghui Pharmaceutical | phase 2 | 3 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rule | wigen-biomedicine-technology-shanghai-co-ltd | phase 2 | 2 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rule | compass-therapeutics | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07362459Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Jul 2027 | 246 |
| NCT06304818Advanced Malignant Solid Tumours | 2 | Not yet recruiting | Dec 30, 2027 | 515 |
How it is read
Names in the registry
- “SCTB14”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.